IP Library Granted Patent US 7,892,522
Granted Patent B2
US 7,892,522 · App. 09/950,985 · Granted Feb 22, 2011

Contrast agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,892,522
App. No.
09/950,985
Granted
Feb 22, 2011
Kind
B2
Abstract

Ultrasound contrast agents comprising microbubbles of biocompatible gas, e.g. a sulphur halide or a perfluorocarbon, stabilized by opsonisable amphiphilic material, e.g. a membrane-forming lipid such as a phospholipid, especially a negatively charged phospholipid such as a phosphatidylserine, may exhibit prolonged contrast-generating residence time in the liver following intravenous administration.

Claims (10)

1. A method of ultrasound imaging which comprises administering to a human or non-human animal subject a contrast-enhancing amount of a contrast agent comprising microbubbles of biocompatible gas stabilised by encapsulating membranes comprising monolayers of opsonisable phospholipid material including at least 50% of negatively charged phospholipid, wherein said negatively charged phospholipid comprises at least one phosphatidylserine, whereby at least a proportion of said membrane-encapsulated microbubbles are taken up in the liver of the subject and exhibit a contrast-generating residence time of 2-8 hours following such administration, and generating an ultrasound image of said uptaken contrast agent microbubbles in at least a part of the liver.

2. A method as claimed in claim 1 wherein said biocompatible gas is sulphur hexafluoride, disulphur decafluoride, a perfluoroacetone, a perfluorodiethyl ether, or a perfluorocarbon.

3. A method as claimed in claim 2 wherein said perfluorocarbon is a perfluorobutane.

4. A method as claimed in claim 1 wherein said biocompatible gas is selected from air, nitrogen, carbon dioxide, oxygen, hydrogen, nitrous oxide, an inert gas, an optionally halogenated low molecular weight hydrocarbon, a sulphur halide and mixtures of any of the foregoing.

5. A method as claimed in claim 1 wherein a substance capable of stimulating blood flow in the liver and/or a substance capable of increasing hepatic uptake by stimulating phagocytosis is administered before, during or after administration of said contrast agent.

6. A method as claimed in claim 1 wherein the ultrasound image is generated by second harmonic imaging.

7. A method as claimed in claim 1 wherein the ultrasound image is generated using techniques based on non-linear effects.

8. A method as claimed in claim 1 wherein generation of the ultrasound image is commenced 5-30 minutes after administration of the contrast agent.

9. A method as claimed in claim 1 wherein generation of the ultrasound imaging is effected using B-mode or Doppler imaging.

10. A method as claimed in claim 1 wherein generation of the ultrasound image is effected at low ultrasound intensity levels using multiple scans.

Assignments (2)
CHANGE OF NAME Recorded Aug 2, 2006
From: AMERSHAM HEALTH AS; NYCOMED IMAGING AS
To: GE HEALTHCARE AS
Reel/Frame 018039/0537 →
CHANGE OF NAME Recorded Jul 29, 2003
From: NYCOMED IMAGING AS; NYCOMED AS
To: AMERSHAM HEALTH AS
Reel/Frame 013838/0444 →